SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Prospector who wrote (2621)7/6/1998 2:51:00 PM
From: jmt  Read Replies (4) of 5402
 
Sir:

Please inquire on the questions listed below, some of which were part of the valuation model proposed by Mr. Forthright.

1) What is the total market potential (in units) for synthetic red blood cell products?

2)What might the product sell for per unit? What is the cost to manufacture per unit?

3) What kind of market share/penetration (in percent) is SGNC expected to achieve?

4) When is SGNC's product expected to get to market?

5) What is the currently available cash and marketable securities balance?

6) What is the current "burn" rate?

7) Where might the next financing be acquired, and how might the financing be structured (debt, equity, convertable preferred)?

Thank you for your attention.

jmt
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News